ERBB2 and breast carcinoma: Amongst these, the single-arm, multicentre phase II Adjuvant Paclitaxel and Trastuzumab (APT) trial included patients with T1–2N0–N1mic HER2+ breast cancer treated with upfront surgery followed by radiation therapy (for breast-conserving surgery only).